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Abstract 
Adjuvant endocrine therapy (AET) has substantially improved the mortality rate among breast cancer survivors. Despite 
the proven efficacy, the non-adherence rate to therapy is still high. This study is aimed to examine women’s challenges 
related to AET adherence and management. Semi-structured interviews were conducted with six Caucasian and six 
African American breast cancer survivors who were prescribed for AET. The transcripts of audio-taped interviews were 
qualitatively analyzed. Key themes were: 1) positive beliefs in AET, 2) uncertainty about long-term adherence, 3) 
experiences with side effects, 4) forgetting and remembering, 5) other concerns and information needs, 6) potential 
intervention format, and 7) culturally-coping among African American women. The findings provided insight into 
women’s experiences and beliefs and how these behaviors might influence AET adherence. Although most women in 
this study took AET as prescribed, many experienced a range of side effects and emotional distress, often without 
seeking support or help. New models of programs to promote adherence, support symptom management, and ultimately 
improve survival are critically needed. Developing culturally sensitive interventions for African American women is 
desirable. 
 
Keywords 
Breast cancer survivorship experience, medication adherence, adjuvant therapy, qualitative interview, perceptions 
 
Notes 
Research reported in this publication was supported in part by Agency for Healthcare Research and Quality K01 
HS019001 (PI: Kuang-Yi Wen) and McKesson Foundation Mobilization for Health grant (PI: Kuang-Yi Wen). We 
thank Kathy Ireton for her administrative assistance. We especially are grateful to all the women who participated in the 
study. The authors have no conflicts of interest to disclose. 
 
 
Introduction 
 
Both national and international guidelines have 
recommended the long-term use of tamoxifen and 
aromatases inhibitors (AIs) for breast cancer surveillance 
management over the past few decades 1,2, and recently, 
updated guidelines recommended 10 years of adjuvant 
endocrine therapy (AET) in women with hormone 
receptor-positive breast cancer 3, approximately 75-80% of 
all breast cancer cases. Despite significant implications for 
survival, adherence to AET, which is prescribed as a daily 
oral tablet, is not optimal with the rate of nonadherence as 
high as 59% for tamoxifen and 50% for AIs in some 
studies 4. The cost of non-adherence to AET is significant 
resulting in lost quality-adjusted life-years, increased 
medical costs, and increased mortality, highlighting the 
importance of developing adherence-promoting 
interventions for this fast-growing population 5.  
 
Breast cancer survivors have consistently reported that 
severe adverse events and side effects, or concerns of their 
development, are reported as a major barrier to 
discontinue AET 6-13. Common side effects of tamoxifen 
include gynecological symptoms such as vaginal bleeding 
and discharge 11. AIs use may be accompanied by 
musculoskeletal problems (i.e., arthralgia and 
osteoporosis), cardiovascular effects, and sexual 
dysfunction 11,14. Both therapies are associated with an 
increase in vasomotor symptoms (i.e., hot flashes) and 
cognitive impairment 11. Emerging quantitative studies 
have linked factors of cost, doctor-patient communication, 
health beliefs, fear of recurrence, self-efficacy, and lack of 
information and social support to intentional non-
adherence 15,16,17,18. To date, qualitative studies in 
adherence research in patients taking oral anticancer drugs 
are emerging but still limited. Gaining an in-depth 
knowledge of the important factors that contribute to 
women’s beliefs about the use or discontinuation of AET 
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will allow us to develop intervention strategies promoting 
women’s long-term adherence. Further, studies have 
reported that compared with other racial/ethnic groups, 
African American women have a higher rate of 
discontinuation of AET treatment, which might contribute 
to the differences in breast cancer mortality between 
African American and White women 1, 2, 21. Thus, 
understanding African American women’s unique 
experience and developing tailored strategies to enhance 
adherence to AET may help reduce disparities in breast 
cancer outcomes between African American and White 
women.  
 
The goal of this qualitative study is to investigate women’s 
barriers and facilitators to their adherence to AET and 
experiences with AET-related symptoms, and to explore 
any racial differences between Caucasian and African 
American women in their experiences and needs. 
 
Methods 
 
Sample 
Participants were recruited from Fox Chase Cancer Center 
(FCCC) in Philadelphia, Pennsylvania, USA. Participants 
were women who had been diagnosed with primary breast 
cancer and had been prescribed Tamoxifen or AI between 
one and five years after primary treatment completion. 
Women taking endocrine therapy as part of treatment for 
metastatic disease were excluded, as this study focused on 
the perspectives of women taking AET to prevent 
recurrence. African American women were purposively 
sampled for the study. Sixteen women were approached 
and screened for the study; two ineligible, two with no 
interest, resulting in a total of six White and six African 
American women participating in the interview. 
 
Table 1 summarizes participant’s demographic and 
medical characteristics (n=12). The mean age of 
participants was 52 years (range 33-72). The majority of 
the participants had some college (66.7%), reported an 
annual household income of more than $30,000 (58.4%), 
were unemployed (66.7%), were married (66.7%). Seven 
women were diagnosed either with stage II or stage III 
breast cancer (58%) and the majority completed 
chemotherapy (88.3%). Five women were prescribed 
Tamoxifen and seven were prescribed an AI daily. In 
average, women had been taking AET for two years. 
While taking AET, four women stated they never missed 
their AET tablets but seven reported they had occasionally 
missed their tablets. One women had stopped AET 
temporarily and another stopped permanently following 
her own volition.  
 
Procedures 
The study was approved by the FCCC Institutional Review 
Board. Recruitment of study participants occurred 
between June and December 2014. Women were recruited 
through clinician referral, study registry, and in person 
approach in medical oncology practices. Eligible women 
signed a consent form and completed a short demographic 
and medical characteristics survey before the interview. 
Interviews were conducted by the lead researcher (KYW) 
or the trained research coordinator (RS) in a private 
consultation room. Interviews lasted between 20 minutes 
and 1 hour. All participants received a $10 gift card for 
their time and effort.  
 
Measure 
The interviews were semi-structured and informed by 
topics from two recent review of factors associated with 
AET use 19,20. The interview guide was designed to probe 
topics on their understanding and expectations of AET, 
their experience with taking AET as prescribed, their 
experiences with AET-related side effects, and their 
suggestions on how to improve AET adherence and 
symptom management.  
 
Analytic Strategies  
Interviews were recorded, transcribed and checked for 
accuracy. Two phases of analysis were conducted. Initial 
coding was carried out using an a priori coding scheme 
based on the interview guide questions 21. After the first 
round of coding, a research team group discussion was 
held to elicit new themes emerging from the data and to 
further refine the coding framework to include sub-themes 
that describe more concrete units of the higher-level 
themes. Themes and sub-themes were iteratively extracted, 
discussed, and agreed on by all research team members 22. 
 
Results 
 
Analysis identified seven themes: 1) positive beliefs in 
AET; 2) uncertainty about long-term adherence; 3) 
experiences with side effects; 4) forgetting and 
remembering; 5) other concerns and information needs; 6) 
potential intervention format and 7) coping among African 
American women.  
 
Theme 1:  Positive Beliefs in AET  
Reasons to take AET was greatly shaped by 
participants’ perceptions and beliefs about the 
benefits of the therapy among this small group of 
women who adhered to AET.   
 
For survival.  Most women stated that they knew the 
therapy was important for their long-term survival, 
and that was the reason for taking their prescribed 
AET. 
 
The oncologist explained to me the benefits long term 
of taking it, and that is why I continued to take it.  
[3-year survivor, White] 
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I know it is one of the things that you have to do or 
you don’t have to, but I choose to based on the 
research.  It is kind of what it is to survive. [1-year 
survivor, White] 
 
Benefits outweigh the risks.  Many women spoke 
about their fear of cancer recurrence motivating them 
to take their AET medication regardless of the side 
effects. They believe the benefits of their therapy 
outweigh the risks. 
 
I guess the benefits, in my opinion, outweigh the risk 
and the side effects. [1-year survivor, White] 
 
Table 1. Demographic and Medical-Related Characteristics of Participants  
 
Characteristics 
n (%) 
Total  
n = 12 
White 
n = 6 
African American 
n = 6 
Age (Mean, SD) (range 33-72) 52 (11.8) 55 (6.0) 50 (14.5) 
Education     
     Some college  8 (66.7) 4 (66.7) 4 (66.7) 
     College complete 4 (33.3) 2 (33.3) 2 (33.3) 
Household income    
     < $30K 5 (41.7) 2 (33.3) 3 (50) 
     $30K to $60K 5 (41.7) 2 (33.3) 3 (50) 
     $60K and above  2 (16.7) 2 (33.3)  
Employment     
    Employed  4 (33.3) 2 (33.3) 2 (33.3) 
    Unemployed 7 (58.3) 4 (66.7) 3 (50) 
    Retired  1 (8.3)  1 (16.7) 
Marital status     
    Married  8 (66.7) 6 (100) 2 (33.3) 
    Married separated/divorced 2 (16.7)  2 (33.3) 
    Never married  2 (16.7)  2 (33.3) 
Breast cancer stage    
    I 5 (41.7) 2 (33.3) 3 (50) 
    II/III 7 (58.3) 4 (66.7) 3 (50) 
Treatment completion     
    Lumpectomy 7 (58.3) 2 (33.2) 5 (83.3) 
    Mastectomy  4 (33.3) 3 (50) 1 (16.7) 
    Chemotherapy 10 (83.3) 5 (83.3) 5 (83.3) 
    Radiation  9 (75) 3 (50) 6 (100) 
AET medication     
   Tamoxifen  5 (41.7) 2 (33.3) 3 (50) 
   AI: Exemestane  2 (16.7)  2 (33.3) 
   AI: Letrozole 2 (16.7) 2 (33.3)  
   AI: Anastrozole 3 (25) 2 (33.3) 1 (16.7) 
Years on AET (Mean, SD) 1.9 (1.2) 1.8 (1.6)          2 (0.9) 
   1 year 6 (50) 4 (66.7) 2 (33.3) 
   2 - 3 years 5 (41.7) 1 (16.7) 4 (66.6) 
   4 - 5 years 1 (8.3) 1 (16.7)  
Ever miss a tablet while taking it    
   No 4 (33.3) 3 (50) 1 (16.7) 
   Yes  7 (58.3) 3 (50) 4 (66.7) 
   Unsure  1  (8.3)  1 (16.7) 
Currently taking     
   Yes 10 (83.3)   
   Stopped temporarily  1 (8.3)  1 (16.7) 
   Stopped permanently  1 (8.3) 1 (16.7)  
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Personally, I thought it was to my benefit for me to 
take the medication even with the side effects. [4-
year survivor, African American] 
 
While I am on it, the cancer won’t come back.  That 
is the reason why I am taking it and going through 
what I am going through because I don’t want the 
cancer to come back. [4-year survivor, African 
American] 
 
Extra protection.  Some women perceived taking 
AET after primary treatment as a maintenance drug. 
This makes them feel that they have extra protection 
against a recurrence of breast cancer, and that they 
have control over their health. 
 
I feel it is a maintenance drug after having breast 
cancer. [1-year survivor, White] 
 
I feel better knowing that I am on something that I 
feel is preventive, so I guess I feel a little safer taking 
something rather than being completely without 
treatment. [2-year survivor, White] 
 
Theme 2:  Uncertainty about Long-Term Adherence 
Is 10 the magic number for Tamoxifen?  Although 
being currently compliant, some women who have 
been on Tamoxifen have expressed their uncertainty 
or confusion about extending the use of Tamoxifen 
from 5 years to 10 years, given the new updated 
guideline. Two women explicitly spoke about their 
concern of the increased risk of uterine cancer with 
possible longer duration of Tamoxifen use.  
 
I am starting to hear that you might benefit from 
being on it longer, so when I hit my five-year mark, 
that will be a big concern … Going off of it is going 
to be a concern because you kind of feel like once you 
go off medication, what’s going to happen? So, it is 
like a roller coaster of emotions … I am concerned 
about effects that can happen down the line ... I 
think I have read that it can cause thickening of your 
uterine lining.  [2-year survivor, African 
American]  
 
I was told two different time frames. One time, I was 
told 5 years and then the next time, 10 years … 
they told me we would look at it when I get closer to 
the 5-year point … my concern is I have an 
increased risk of uterine cancer while on it.  [1-year 
survivor, White] 
 
Uncertainty in the context of not knowing.  Women 
talked about their lack of information on the 
medication itself and related side effects, especially 
the impact of the medication in the long term. 
Uncertainty about the impact of the medication on 
survival or adverse effects might contribute to 
potential nonadherence beliefs.    
 
Is this just the side effect I will have for five years or 
will there be other side effects that will follow, or how 
is it going to work afterward, I do not know. I am 
not going to drop the medicine yet, but honestly, I 
don’t think I am going to take it for 5 years.  [1-
year survivor, White] 
 
I do not have much information on the medication, 
like the side effects and like the outcome…when you 
take an antibiotic and you take it for 5 days, and 
you start feeling better … it’s like I am taking this 
hoping that it will repress the cancer cells, but do I 
have or don’t I have cancer cells? I am just taking it 
in the dark.  [2-year survivor, African 
American] 
 
Theme 3:  Experiences with Side Effects 
Although most women reported taking their 
medication as prescribed, many described their 
challenging experience with side effects both 
emotionally and physically.  
 
Frustration with symptoms.  Several provided 
graphic descriptions of extreme symptoms including 
hot flashes and night sweats, joint and bone pains, 
vaginal dryness, insomnia, weight gain, diarrhea, 
fatigue, and mood swings.   
 
I get very, very hot like in my face and all around my 
body … I have to take all my covers off immediately 
... and like in ten minutes, I get this chill going 
through my body … when it starts, it goes back and 
forth for a while. [1-year survivor, White] 
 
I had insomnia for about three months. I couldn’t go 
to sleep. I slept for maybe two to three hours within a 
day. [2-year survivor, African American] 
 
I have the ups and downs ... you know, one day I 
am up and one day I am down ... I can feel like 
when I am becoming angry, and I don’t know why, 
or if I am just feeling like depressed. [2-year 
survivor, African American] 
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I have new aches, I have back pains, I have 
headaches. I could be fine today and tomorrow, I can 
be sick as a dog. [4-years survivor, African 
American] 
 
Impact of symptoms.  Some women described the 
profound impact that side effects had on their daily 
lives. Side effects, such as fatigue, impede women in 
performing their normal daily activities. 
 
I was never told that I would have been incapacitated 
to the point where it would be difficult getting out of 
bed to shower and dress and to just do those things in 
normal daily living. [2-year survivor, African 
American] 
 
I am going through so much with this new medication 
that I am taking, that I have not worked a full week 
since this year. [4-year survivor, African 
American] 
 
Emotional adjustment.  Some described the impact 
of side effects on their emotional wellbeing. Their 
distress was also caused by the deterioration of their 
body image and impaired efficiency because of 
tiredness and hot flushes.  
 
I was psychologically unprepared to the extent of the 
side effects because I have been an extremely busy, 
active person … but the medication did something to 
me emotionally where I couldn’t do it ... so not being 
able to function in the capacity that I am used to 
doing really affected me psychologically [4-year 
survivor, African American] 
 
It affected my skin, became dry, my hair became 
brittle ... everything is dropping and sagging. The 
emotional effects of going through menopause for me 
was the most challenging, where the physical effects 
not so much for me. [2-year survivor, African 
American] 
 
The side effects caused a lot of my negative attitude. 
[1-year survivor, White] 
 
Coping with symptoms.  Several women reported 
that their providers suggested they take the 
medication at night to avoid the symptoms. Women 
also reported using supplements to cope with 
symptoms.  
  
The nurse recommended taking it at night because 
with the symptoms that can happen, it might be more 
tolerable while you are sleeping over night as opposed 
to in the middle of the day, so I take mine before I go 
to bed and that did work for me.  [2-year 
survivor, African American] 
 
I started to take the vitamin B. It helped my energy 
level. I am still tired, but not as tired as I was a few 
months ago. [2-year survivor, African 
American]  
 
I take this with a vitamin D 200 for my bones and 
my age. [4-year survivor, African American] 
 
I have a lot of bone pain, and I do have arthritis and 
my calcium level is low, so I am taking calcium pills.  
[4-year survivor, African American] 
 
About two months of being on the medication, I 
began to have chronic diarrhea. I started to take a 
probiotic and it helped.  [3-year survivor, White]  
 
Theme 4.  Forgetting and Remembering 
Unintentional non-adherence.  Women reported 
unintentional non-adherence, which was usually a 
result of an unestablished routine at the initiation of 
the therapy or an interrupted routine because of 
change of personal schedule. Feeling tired or sick was 
also reported interfering with staying on their 
medication schedule.  
 
At the beginning, I didn’t remember if I took it or 
not. [4-year survivor, African American] 
 
Sometimes, it takes a while to get into the routine to 
remember to take it. I am sure there were many days 
that I missed, one here and there. [5-year survivor, 
White] 
 
When I am out maybe on the weekend or at a 
conference. I did not bring my pill bottle with me. It 
is like a break of my normal routine.  [2-year 
survivor, African American] 
 
Sometimes, I missed a day or two because I get too 
tired and I fall asleep.  [2-year survivor, African 
American] 
 
Strategies to aid in remembering.  Women reported 
different strategies that helped them remember to 
take their medications including using visual cues 
Patient experience of taking adjuvant endocrine therapy, Wen et al. 
  
 
 
109 Patient Experience Journal, Volume 4, Issue 3 – 2017 
(e.g., by the bed), external aids (e.g., a reminder app), 
and organization medicines (e.g., a pillbox). As a 
result of implementing these strategies, women were 
able to integrate taking their medication as part of 
their daily routine.   
 
I take it at night.  I just remember to take it like a 
birth control pill, that is how I look at it. [2-year 
survivor, African American] 
 
I know every time that I eat lunch, I take my 
medication. I keep the bottle in my pocketbook, so 
when I go to lunch, I take my phone, and when I 
take my phone, I always see the medication in my 
pocketbook. [4-year survivor, African 
American] 
 
My bottle is right next to my bed, so typically, like 
10’oclock is when I start winding down, so that is 
sort of my routine. [2-year survivor, African 
American] 
 
I have a pillbox, and basically, my reminder is when 
I give my husband his insulin at 9 and I take my 
pill.  [1-year survivor, White] 
 
I have an app on my phone. At the time, the app 
sends you a reminder and if you don’t click I took 
my medication in like 15 minutes, it plays a tune. 
[1-year survivor, White] 
 
I take it every night after dinner, as a joke, they call 
it my staying alive pill, and we always joke about it 
so I took it. [2-year survivor, White] 
 
Theme 5.  Other Concerns and Information Needs 
Impact of medication on fertility.  A main concern 
that was reported by younger participants is the 
fertility issue. They were worried about their fertility 
status and wanted a clear understanding on the 
impact of the medication on family planning.  
 
Me and my husband discussed he wants another 
baby, and with me being on the Tamoxifen, they told 
me I couldn’t have children. So that’s the only thing 
that is a big problem in my personal life, that might 
be one of my questions when I go to the doctor. [2-
year survivor, African American] 
 
I know that I have to be on it for 10 years, but what 
I want to know is, if after 10 years, would I be able 
to become pregnant? [2-year survivor, African 
American] 
 
Drug interactions. Given comorbidities are not 
uncommon among cancer patients, some women 
expressed their concern about the timing of taking 
their AET in relation to other chronic disease drugs 
and any potential drug interaction that they should be 
aware of.   
 
If someone is new to the Tamoxifen and they are 
taking different medications, the hospital should say 
okay this drug is compatible with this drug so that 
way, for people who take different medication, 
Tamoxifen might not be good for me or I can’t mix 
the medication. [2-year survivor, African 
American] 
 
I normally take Arimidex in the morning after 
breakfast, then I normally take my blood pressure 
medications in the evenings because I don’t know, I 
haven’t been told if there are any contraindications to 
taking all of them together. [2-year survivor, aged 
62, African American] 
 
Nutrition and Diet.  Some participants discussed 
their desire to receive information on nutrition and 
to have opportunities to discuss their dietary 
questions with a dietitian. They would like to receive 
practical advice on food selection during AET. 
Dietary information includes types of foods to eat to 
minimize side effects from AET, particular vitamins 
and minerals to help prevent cancer recurrences, and 
general nutrition information to feel better.  
 
One thing that was lacking with the medication was 
the proper nutrition [4-year survivor, African 
American] 
 
I would love to be able to be in touch with researchers 
who are doing work with natural remedies to prevent 
recurrence of breast cancer. I would love to be in 
touch with a nutritionist to learn how to eat well.  
[2-year survivor, African American] 
 
Theme 6:  Potential Intervention Format 
Following the interview about AET experiences and 
concerns, survivors were asked “how” to get the 
support or information they desire.  
 
Intervention delivery modality.  When discussing 
what could have helped women learn about and 
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continue to use AET, some participants brought up 
the idea of using portal websites that present 
individual prescription and related information that 
can be easily accessible. Using a portable feature on a 
cell phone or using text messaging was also 
mentioned as a potential modality for delivering any 
medication tips and reminders.  
    
If you are able to have like our medications in a 
portal website where you can go to and there would be 
resources available specific to the prescriptions that 
you are on and symptoms that you can kind of look 
up [2-year survivor, African American] 
 
If there are any tips to help me to remember to take 
it on a daily basis instead of skipping occasionally.  
Some reminder, like portable on my phone. [5-year 
survivor, White] 
 
Because if I do forget, text messages would be an 
extra back-up to remind me. [2-year survivor, 
White] 
 
Long-term follow-up.  While some women reported 
receiving information about AET from their 
providers at the time of treatment initiation, they also 
expressed that it was difficult to recall the 
information they had initially received, or it was too 
overwhelming to comprehend the information at the 
time. The possibility of a long-term follow-up to 
reiterate the importance of AET and potential new 
side effects was suggested.  
 
Maybe after a year or two or maybe two or three 
years, another reminder of possible side effects. I 
know they gave me a handout, but I don’t know 
what I did with it. [5-year survivor, White] 
 
My provider gave me a lot of information which I 
was not able to truly initially comprehend I was so 
upset. [4-year survivor, African American] 
 
Theme 7:  Coping Among African American Women 
Religion and spiritual coping.  Our data suggest that 
religion and spirituality might play a major role in the 
lives of our African American participants. In our 
study, African American women coped with their 
symptoms and fear of recurrence through their 
religious and spiritual beliefs. Their positive 
perceptions were empowered by their faith in God.  
 
I prayed about it (Tamoxifen) and went to God, and 
I knew that everything was going to be ok. [2-years 
survivor, African American] 
 
Through prayers, lots of meditation, it is a lot better, 
but I am still dealing with the emotional part of it 
(side effect). [4-year survivor, African 
American] 
 
I have a strong belief in God. I have a strong belief 
in prayer. I feel that when I found my tumor myself 
is a gift from God. [2-year survivor, African 
American] 
 
Peer-support.  Relationship with other breast cancer 
survivors was reported important to most of our 
African American participants. In some instances, 
they shared information and support with other 
breast cancer women, either one-on-one or through 
support groups.  
 
I have started a breast cancer survivor group at my 
church for women diagnosed and going through the 
daily day-to-day problems. [2-year survivor, 
African American] 
 
Talking to some close friends who have gone through 
the medication. I am involved in my church cancer 
program, and I am asked to comment on it so other 
people have been led to me because of my experience. 
[4-years survivor, African American] 
 
I found that the Facebook group that I belong to is 
really helpful for me, you post things or I see other 
women posting things, and everybody kind of chimes 
in and that’s helpful. [2-year survivor, African 
American] 
 
Discussion 
 
The aim of this study was to explore and understand 
women’s experiences and adherence behaviors after 
initiation of AET from 1 to 5 years. As found in other 
studies, most of the women interviewed in this study 
believed that taking the prescribed AET would improve 
their survival, despite the presence of side effects. This 
finding is consistent with the “necessity-concern” model 23 
in that women who adhere to the therapy trusted and 
believed that the medication will prevent the recurrence of 
cancer, which to them was a motivation to adhere to the 
therapy although they had to tolerate significant side 
effects. The type and nature of AET-related side effects 
reported in the interviews were consistent with previous 
Patient experience of taking adjuvant endocrine therapy, Wen et al. 
  
 
 
111 Patient Experience Journal, Volume 4, Issue 3 – 2017 
clinical reports in the literature 24,25. However, women 
reported receiving little support from their providers and 
the magnitude of symptoms sometimes strongly interfered 
with their daily activities. Further, providers might perceive 
side effects that affect the quality of life of patients taking 
AET are usually not life-threatening and differ from those 
that providers are mostly concerned about 26. Therefore, 
AET-related symptom information might not be discussed 
with patients comprehensively. Unbiased and objective 
information about AET side-effects for patients is desired 
and critical. As the recommended duration of AET is 
being extended 27, management of these symptoms is 
becoming increasingly important because these side effects 
can adversely impact both patient’s quality of life and 
adherence to prescribed treatment. Future research needs 
to develop effective interventions to address a patient’s 
doubt about the necessity for AET and concerns about 
side effects to enhance adherence. 
 
Most women in our study believed that they were adherent 
and had implemented strategies in establishing a daily 
routine to help them remember to take their tablets. These 
routines generally consisted of a combination of keeping 
the medication somewhere they would be seen and/or 
taking the medication at a very specific time each day. 
Occasionally, forgetfulness usually occurred when the 
routine was not established yet (e.g., at the beginning of 
treatment initiation) or when the routine was interrupted 
(e.g., on vacation). Therefore, future research needs to 
inform initiation of care, where patterns of behaviors are 
established and carried out through the entire AET 
treatment regimen.       
 
While patients of all ages may contend with challenges 
surrounding their treatment, younger women, who are 
interested in having biological children after treatment, 
face added complexity. Consistent with previous studies 
that younger women have questions regarding fertility 28, 
our data suggest that some younger women might have 
unmet information needs about their fertility status during 
or after AET treatment. Interest in receiving fertility-
related information was even identified among those who 
already have children at diagnosis, suggesting the 
importance of not overlooking the fertility issue among 
breast cancer patients with children. Clinicians need to be 
aware of and have an understanding for their younger 
patients’ values regarding childbearing in order to assist 
them to make truly informed decisions and, thereby, 
adhere with their AET treatment.  
 
Cancer patients often receive numerous medication, 
including anticancer drugs and drugs to treat comorbid 
conditions. These multiple treatments increase patient’s 
uncertainty about drug interactions and any potential 
adverse effects, as suggested in our patient’s responses. 
Considering that a significant number of patients with 
hormone receptor-positive breast cancer would use AET 
treatment in the future, communication about the safety 
use of other drugs in relation to AET is an important part 
of survivorship care. Furthermore, our findings are also 
similar to those of previous studies that showed breast 
cancer patients desire information regarding nutrition and 
diet 29. In particular, some of our participants expressed 
their strong desire to receive information about what to 
eat that would ease the AET-related side effects and 
improve their survival. Despite the availability of a range 
of resources and information sources that exist on the 
subjects of diet and nutrition in cancer, breast cancer 
patients continue to report unmet needs in the area of diet 
30,31, perhaps indicating available information lacks 
specificity (e.g., in the context of AET). Our findings 
suggest an increase in provision of diet and nutrition 
information during AHT is needed.        
 
Although previous interventions with patient educational 
materials and phone reminders have had minimal success 
in increasing AET adherence 32-34, as some of our 
participants mentioned, future interventions should 
consider how to use technology (websites or text 
messaging or other “out-of-the-box” approaches) to 
promote AET adherence. Text messaging is one of the 
most accessible forms of mHealth communication, and 
evidence is emerging on the use of text messaging for a 
wide range of health and behavioral programs including 
medication adherence 35. Text messaging might be an 
effective modality to promote AET adherence, as it can be 
integrated into women’s daily life and adapted to individual 
needs in real time 36. Using web-based or mobile platforms 
to offer medication reminders, symptom management, 
compliance comparison with the patient population, and 
survival rate improvements could be used to encourage 
women to comply with treatment recommendations. 
Future research should aim to quantify preferences for 
information tools and communication strategies in a larger 
sample with a focus on tailoring the interventions for 
women with different information needs and cultural 
ethnic background. Longitudinal interventions with long-
term follow-ups at different time points to reiterate the 
importance of AET and strategies for managing new side 
effects would be also important, as updated guidelines 
recommend consideration of 10 years of AET in women 
with hormone receptor-positive breast cancer 27.  
 
Our findings suggest that religion and spirituality were 
important components in our African American women’s 
breast cancer experience. Previous research showed that 
faith in God helped African American women cope during 
and after treatment, as they believed they could endure 
their treatment and related side effects and ultimately 
survive the disease 37,38. Further, the benefit of peer-
communication was suggested in our African American 
subgroup. Therefore, future interventions targeting 
African American breast cancer women might want to 
consider utilizing spiritual ties or peer-led approaches for 
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strengthening AET beliefs and promoting its adherence. 
Additional research focusing on African American breast 
cancer women’s experience with AET is needed as our 
sample was limited. 
 
Our study was not without limitations. Our sample size 
was small and relatively well-educated, therefore, the views 
expressed by women in our study were not representative 
of the entire population of women receiving AET for their 
breast cancer. Future research should aim to extend our 
findings across a more diverse sample including different 
ethnic groups and low-literate populations. As identifying 
the cultural factors that contribute to ethnic variation in 
AET adherence is important, we also want to emphasize 
that individual patient’s needs might be different, requiring 
personalized care and support. The majority of the women 
in our limited sample adhered to the AET so far, thus, 
findings from their experience might not be informative 
about non-adherence. Women who stopped AET 
completely were under-represented in this study (only one 
in our sample). It is possible that we were not able to reach 
non-adherent patients due to their loss for follow-up 
survivorship care or the lack of knowledge of their 
clinicians. Further qualitative studies targeting women who 
are known to be non-adherent would enhance the 
knowledge base in this area. Further, participants in this 
study were all recruited at a cancer center, thus participants 
were likely to respond to some doctor-patient relationship 
questions with socially desirable answers. The results 
obtained by the present study might be influenced by 
recollection bias. Prospective studies of women’s AET-
related needs and how their experience change over time 
are critical. 
 
Implications for patient-centered care practice  
 
The findings from our study have several implications for 
patient-centered care practice 39. First, for breast cancer 
patients making decisions to initiate and continue AET, 
information and communication from clinicians are 
important. Clinicians may encourage medication adherence 
by focusing on and communicating the value of the 
medication that the patient is taking, as well as providing 
complete and unbiased information about potential side 
effects. Second, clinicians need to listen to and respect 
patient’s perspectives, concerns, and cultural beliefs about 
AET so that doctor-patient communication can be 
adjusted accordingly to positively influence patient 
medication adherence. Third, patients and families need to 
be encouraged with tools and resources to participate in 
decision-making about AET and in management of 
adherence behaviors and side effects through collaboration 
with clinicians. Taken together, our findings provide 
insight into the needs and experience of breast cancer 
survivors prescribed for AET. Although women in our 
study are generally highly compliant with their AET 
despite significant negative side effects, women’s insights 
provide opportunities for targeted interventions to 
improve survivor’s experience and symptom management, 
which could ultimately improve adherence, quality of life, 
and survival.  
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